Step Pharma will present CTPS1 inhibiton results at EULAR 2021 (June 2-5)

Paris, France, May 31, 2021 – Step Pharma will be present at EULAR 2021 (June 2-5, 2021) to present results on inhibition of CTP Synthase 1 on T-cells and B-cell proliferation.

Step Pharma to present a poster on STP938 at 12th International Congress on AutoImmunity

Paris, France, May 21, 2021 – Step Pharma will present at the 12th International Congress on AutoImmunity. Listen to our poster presentation on Monday 31st May.

Step Pharma awarded ‘First-in-class therapeutic innovation' during the 6th MEET2WIN Oncology Convention

Paris, France, 11 May 2021 – Among eleven pre-selected projects, Step Pharma SAS have been selected by the MATWIN board, based on its relevance from a medical perspective and their future development potential. More on MATWIN, click here


Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies

Archamps, France, 24 March 2021

Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing. New investors Hadean Ventures and Sunstone Life Science Ventures co-led the round, joining existing investors Kurma Partners, Pontifax and Bpifrance, who reinvested through its Innovative Biotherapies and Rare Diseases fund and InnoBio 2 fund. As part of the financing, Jacob L Moresco from Sunstone Life Science Ventures and Walter Stockinger from Hadean Ventures will join the Step Pharma Board of Directors.

The proceeds will be used to advance Step Pharma’s lead proprietary CTPS1 inhibitor, STP938, into clinical development for the treatment of T-cell malignancies. In addition, Step Pharma will use the funding to advance development of CTPS1 inhibitors in other haematological malignancies and solid tumours. CTPS1 (cytidine triphosphate synthase 1) is an enzyme that plays a critical role in DNA synthesis, cell division and proliferation but whose function is highly selective to certain cell types, in particular proliferating T cells, making it an ideal target for drug development.

Roger Franklin, Partner at Hadean Ventures said: “CTPS1 is an elegant target for the development of drugs in the T-cell malignancy space in which there is significant unmet need. The strength of the underlying science, its support from human genetic work as well as the clear commercial opportunity were key factors in our decision to back Step and co-lead this significant financing. We very much look forward to working with the great team at Step as this exciting programme moves into the clinic.”

“Step Pharma is a clear leader in CTPS1 research. They have made significant progress in advancing their 1st in class selective CTPS1 inhibitors toward clinical development and expanding the potential therapeutic applications,” added Jacob L Moresco from Sunstone Life Science Ventures

“The closing of this Series B will enable Step Pharma to transform into a clinical-stage company, enabling us to advance our lead compound into the clinic in Q1 2022,” said Andrew Parker, CEO of Step Pharma. “We’d like to welcome our new investors and thank existing investors for their continued support of the company.”

Targeting CTPS1
Cytidine nucleotide triphosphate (CTP) is a precursor required for DNA synthesis and cell division. Patients deficient in the enzyme CTPS1 have an altered immune cell proliferation response to immune challenge but no other deleterious effects. This same pathway supports the uncontrolled growth of cancerous T and B cells, thus inhibiting CTPS1 represents a novel precision oncology approach to specifically block proliferation and induce killing of cancerous cells in lymphoma and leukemia.

About Step Pharma
Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of oncology and autoimmune diseases. The company has identified several inhibitors of CTPS1, with the most advanced, STP938 being prepared for clinical studies in T-cell malignancies.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour’s laboratory at the Imagine Institute, Paris. Step Pharma is based in Archamps, France. More information on the company can be found at

Step Pharma 
Andrew Parker
Tel: +33 (0) 7 81 54 80 61

Halsin Partners
Mike Sinclair
Tel: +44 (0) 207 318 2955


Download as PDF

Step Pharma to present a poster on STP938 at American Society of Hematology conference

Paris, France, December 1st 2020 – Step Pharma SAS, in collaboration with Sygnature Discovery, has been selected to present a poster named "STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias" at the American Society of Hematology (ASH) conference starting December 5th.

Step Pharma selected by a panel of 15 European investors as a winner in the MATWIN OUI event

Paris, France, 23 October 2020 – Step Pharma SAS have been ranked 1st among eleven cancer research companies by the MATWIN second OUI (Oncology Upward Investment) investor event, designed to help secure financial backing for promising innovations. More info (Matwin press release).